1
|
Yang Q, Sun K, Gao T, Gao Y, Yang Y, Li Z, Zuo D. SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells. Mol Carcinog 2024. [PMID: 39078281 DOI: 10.1002/mc.23799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 07/16/2024] [Accepted: 07/19/2024] [Indexed: 07/31/2024]
Abstract
Most EML4-ALK rearrangement non-small cell lung cancer (NSCLC) patients inevitably develop acquired drug resistance after treatment. The main mechanism of drug resistance is the acquired secondary mutation of ALK kinase domain. L1196M and G1202R are classical mutation sites. We urgently need to understand the underlying molecular mechanism of drug resistance to study the therapeutic targets of mutant drug-resistant NSCLC cells. The silent information regulator sirtuin1 (SIRT1) can regulate the normal energy metabolism of cells, but its role in cancer is still unclear. In our report, it was found that the SIRT1 in EML4-ALK G1202R and EML4-ALK L1196M mutant drug-resistant cells was downregulated compared with EML4-ALK NSCLC cells. The high expression of SIRT1 was related to the longer survival time of patients with lung cancer. Activation of SIRT1 induced autophagy and suppressed the invasion and migration of mutant cells. Further experiments indicated that the activation of SIRT1 inhibited the phosphorylation level of mTOR and S6K by upregulating the expression of AMPK, thus activating autophagy. SIRT1 can significantly enhanced the sensitivity of mutant cells to crizotinib, improved its ability to promote apoptosis of mutant cells, and inhibited cell proliferation. In conclusion, SIRT1 is a key regulator of drug resistant in EML4-ALK L1196M and G1202R mutant cells. SIRT1 may be a novel therapeutic target for EML4-ALK drug resistant NSCLC.
Collapse
Affiliation(s)
- Qian Yang
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| | - Keyan Sun
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| | - Tianyu Gao
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| | - Ying Gao
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| | - Yuying Yang
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| | - Zengqiang Li
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| | - Daiying Zuo
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Shenhe District, China
| |
Collapse
|
2
|
Ravindranath KJ, Christian SD, Srinivasan H. Screening of Anti-carcinogenic Properties of Phytocompounds from Allium ascalonicum for Treating Breast Cancer Through In Silico and In Vitro Approaches. Appl Biochem Biotechnol 2023; 195:1136-1157. [PMID: 36331692 DOI: 10.1007/s12010-022-04202-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2022] [Indexed: 11/06/2022]
Abstract
Plants, rich in phytocompounds, have been in usage since time immemorial for treating various diseases, namely, cancer. One such plant species, Allium ascalonicum (Shallot) belonging to Amaryllidaceae family is being studied here for its anti-carcinogenic properties against breast cancer. GC-MS characterization of A. ascalonicum exhibited 48 phytocompounds containing five peak phytocompounds and 13 phytocompounds with anti-carcinogenic properties. These 13 anti-carcinogenic phytocompounds were docked with three hormonal receptors involved in breast cancer malignancy, namely, ERα, PR, and human EGFR with tamoxifen as standard for in silico analysis. The results exhibited three phytocompounds that had better binding scores compared to that of the standard drug, tamoxifen. Lyophilized powder of aqueous A. ascalonicum extract, also referred as ASE, was used for in vitro approaches. Antioxidant study using DPPH assay revealed that the highest percentage of FRSA in ASE, nearly 51%, was observed at 50 µg/ml concentration. Cytotoxicity study on MCF-7 cell line using MTT assay demonstrated IC50 value at 1400 µg/ml and anti-proliferative study using Trypan blue assay for the determination of percentage viability of MCF-7 cells at IC50 concentration was observed to be 49%. Anti-mitotic activity using Vigna radiata seed germination assay revealed clear morphological differences in a dose-dependent manner between the seeds grown at various concentrations of ASE with nearly 56.5% growth inhibition observed at 1500 µg/ml concentration. Hence, this research work proves that Allium ascalonicum has very good anti-carcinogenic properties and this can be confirmed further through in vivo animal model studies and it can also be formulated as a promising drug to treat breast cancer. GC-MS characterization of Allium ascalonicum demonstrated the presence of five peak compounds and thirteen anti-carcinogenic compounds. The thirteen anti-carcinogenic compounds were docked with three target proteins (in silico analysis) involved in breast cancer malignancy and identified the presence of three potential phytocompounds that can be used for treating breast cancer. In vitro approaches also confirmed the presence of anti-carcinogenic properties such as antioxidative potential, cytotoxic, anti-proliferative, and anti-mitotic effects. Hence, Allium ascalonicum can be taken further to in vivo studies so that it can be formulated to treat breast cancer.
Collapse
Affiliation(s)
- Karunya Jenin Ravindranath
- School of Life Sciences, B. S. Abdur Rahman Crescent Institute of Science & Technology, Vandalur, Chennai, 600048, India
| | - Simon Durairaj Christian
- School of Life Sciences, B. S. Abdur Rahman Crescent Institute of Science & Technology, Vandalur, Chennai, 600048, India
| | - Hemalatha Srinivasan
- School of Life Sciences, B. S. Abdur Rahman Crescent Institute of Science & Technology, Vandalur, Chennai, 600048, India.
| |
Collapse
|
3
|
Chang X, Wang J, Bian J, Liu Z, Guo M, Li Z, Wu Y, Zhai X, Zuo D. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. Toxicol Appl Pharmacol 2022; 450:116156. [PMID: 35803438 DOI: 10.1016/j.taap.2022.116156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 06/27/2022] [Accepted: 07/01/2022] [Indexed: 11/19/2022]
Abstract
Anaplastic lymphoma kinase (ALK) belongs to the family of receptor tyrosine kinases. Recently, the incidence of anaplastic large cell lymphoma (ALCL) with ALK rearrangement has raised considerably. The application of ALK-targeted inhibitors such as ceritinib provides an effective therapy for the treatment of ALK-positive cancers. However, with the prolongation of treatment time, the emergence of resistance is inevitable. We found that 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ceritinib derivative, could inhibit the proliferation of ALK-positive ALCL cells, induce the apoptosis of Karpas299 cells through the mitochondrial pathway in a caspase-dependent manner. In addition, ZX-42 could suppress ALK and downstream pathways including PI3K/Akt, Erk and JAK3/STAT3 and reduce the nuclear translocation of NFκB by inhibiting TRAF2/IKK/IκB pathway. Taken together, our findings indicate that ZX-42 shows more effective activity than ceritinib against ALK-positive ALCL. We hope this study can provide a direction for the structural modification of ceritinib and lay the foundation for the further development of clinical research in ALK-positive ALCL.
Collapse
Affiliation(s)
- Xing Chang
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Junfang Wang
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Jiang Bian
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Zi Liu
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Ming Guo
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Zengqiang Li
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Yingliang Wu
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Xin Zhai
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
| | - Daiying Zuo
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
| |
Collapse
|